<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0000935836-25-000423</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: LYTTON LAURENCE W -->
          <cik>0001105806</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001385818</issuerCik>
        <issuerName>AYTU BIOPHARMA, INC</issuerName>
        <issuerCusip>054754858</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>7900 E. UNION AVENUE</com:street1>
          <com:street2>SUITE 920</com:street2>
          <com:city>DENVER</com:city>
          <com:stateOrCountry>CO</com:stateOrCountry>
          <com:zipCode>80237</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>LYTTON LAURENCE W</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>1054752.00</soleVotingPower>
        <sharedVotingPower>31800.00</sharedVotingPower>
        <soleDispositivePower>1054752.00</soleDispositivePower>
        <sharedDispositivePower>31800.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1086522.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The shares of the Common Stock reported herein consist of 122,063 shares of Common Stock and warrants to purchase 1,831,666 shares of Common Stock, subject to a 9.99% beneficial ownership limitation.  The percentages reported in this Schedule 13G are based on 9,911,913 shares of Common Stock outstanding as of September 15, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended June 30, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Lytton-Kambara Foundation</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>1054752.00</soleVotingPower>
        <sharedVotingPower>31800.00</sharedVotingPower>
        <soleDispositivePower>1054752.00</soleDispositivePower>
        <sharedDispositivePower>31800.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1086522.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The shares of the Common Stock reported herein consist of 122,063 shares of Common Stock and warrants to purchase 1,831,666 shares of Common Stock, subject to a 9.99% beneficial ownership limitation.  The percentages reported in this Schedule 13G are based on 9,911,913 shares of Common Stock outstanding as of September 15, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended June 30, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>AYTU BIOPHARMA, INC</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>7900 East Union Avenue, Suite 920, Denver, CO 80237</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Laurence W. Lytton and Lytton-Kambara Foundation ("Foundation")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>467 Central Park West
New York, NY 10025</principalBusinessOfficeOrResidenceAddress>
        <citizenship>USA</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Lytton: 1,086,522

Foundation:  1,086,522</amountBeneficiallyOwned>
        <classPercent>Lytton: 9.99%

Foundation:  9.99%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Lytton:  1,054,752

Foundation:  1,054,752</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Lytton:  31,800

Foundation:  31,800</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Lytton:  1,054,752

Foundation:  1,054,752</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Lytton:  31,800

Foundation:  31,800</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>LYTTON LAURENCE W</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Laurence W. Lytton</signature>
        <title>Reporting Person</title>
        <date>11/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Lytton-Kambara Foundation</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Laurence W. Lytton</signature>
        <title>President</title>
        <date>11/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureComments>Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G</signatureComments>
  </formData>

</edgarSubmission>
